• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

GLP-1 agonist and basal insulin an effective anti-diabetic regimen

byXiaozhou Liu
September 12, 2014
in Chronic Disease, Endocrinology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Compared to other anti-diabetic regimens, patients treated with a GLP-1 agonist and basal insulin combination had a greater mean reduction of HbA1c levels.

2. The GLP-1 agonist and basal insulin combination was associated with significant weight loss in study participants.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Type 2 diabetes is associated with significant mortality and morbidity, including cardiac, renal, vascular, and neurologic complications. While there are many available treatment regimens, each is associated with significant adverse profiles – the most significant adverse effect is hypoglycemia associated with insulin and insulin secretagogues, which limits how aggressive clinicians can be in assisting patients to reach their HbA1c targets. Glucagon-like peptide-1 (GLP-1) receptor agonist, as an incretin mimetic, increases insulin secretion only in the presence of increased blood glucose. As such, GLP-1 agonists are not associated with significant risks of hypoglycemia. Results of a meta-analysis published today in the Lancet showed that the combination of GLP-1 agonist and basal insulin was more effective at lowering HbA1c levels than other regimens, was not associated with increased risks of hypoglycemia, and was associated with significant weight loss in study subjects. The meta-analysis included 15 studies with over 4,000 participants. Between-study heterogeneity were noted and could moderately limit the power of certain conclusions drawn from this meta-analysis.

Click to read the study, published today in The Lancet

Relevant Reading: Type 2 diabetes across generations: from pathophysiology to prevention and management

In-Depth [meta-analysis]: This is a meta-analysis that included 15 studies with 4348 participants. The outcomes assessed were the following: change in HbA1c between baseline and end of intervention, proportion of participants achieving an HbA1c of 7.0% or lower at the end of the study period, and the number of participants with hypoglycemic episodes.

RELATED REPORTS

2 Minute Medicine Rewind February 6, 2023

Sodium-glucose cotransporter 2 inhibitors may reduce incidence of obstructive airway disease

Metformin use in Type 2 Diabetes associated with decreased risk of joint replacement

In a pooled analysis of all 15 trials, the GLP-1 agonist/basal insulin combination resulted in a greater mean reduction in HbA1c than with any other treatment strategy by 0.44% (95% confidence interval, CI, 0.60 to 0.29 reduction). The Egger test showed publication bias (p=0.0047); however, further trim-and-fill analysis showed that this bias did not impact the estimates. There was no significant between-study heterogeneity.

In a pooled analysis of 14 studies, there was a higher likelihood of participants achieving an HbA1c level of 7.0% or lower at the end of the intervention with GLP-1 agonist and basal insulin combination (absolute risk difference, 17.4%) compared with other treatments. There was statistically significant between-study heterogeneity. There was no apparent publication bias (p=0.16).

A pooled analysis of 11 studies showed no significant difference in the relative risk of developing hypoglycemia between GLP-1 agonist/basal insulin combination and other treatments. There was statistically significant between-study heterogeneity and no significant publication bias (p=0.81).

Finally, a pooled analysis of 12 studies showed that GLP-1 agonist with basal insulin treatment led to a greater mean reduction in weight compared to other treatments (-3.22 kg, 95% CI, -4.90 to -1.54), with statistically significant between-study heterogeneity. There was no publication bias detected (p=0.81).

More from this author: New dengue fever vaccine effective in phase 3 trial, Insulin pumps more effective than multiple daily injections in type II diabetics [OpT2mise trial], Heart attack hospitalization rate in China quadruples from 2001-2011, Vitamin D supplementation does not reduce risk of falls, ¹⁸F-FDG PET brain imaging could predict recovery in vegetative patients

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: diabetesinsulin
Previous Post

Coronary angioplasty safe and effective at facilities without on-site cardiothoracic surgery

Next Post

Improved diagnosis of incidental adrenal masses by dual-energy CT

RelatedReports

Prevalence of hypertension among adolescents varies by race and BMI
Weekly Rewinds

2 Minute Medicine Rewind February 6, 2023

February 6, 2023
CPAP may not decrease cardiovascular events in sleep apnea
Endocrinology

Sodium-glucose cotransporter 2 inhibitors may reduce incidence of obstructive airway disease

February 2, 2023
Type 2 diabetes associated with reduction in disability-free life years
Chronic Disease

Metformin use in Type 2 Diabetes associated with decreased risk of joint replacement

January 16, 2023
Pediatric DKA associated with recent acute care visits
Cardiology

Low-carbohydrate, high-fat diet improves glycemic control in type 2 diabetic patients

January 11, 2023
Next Post
Half of parents aware of CT radiation cancer risk

Improved diagnosis of incidental adrenal masses by dual-energy CT

Women electing abortion more likely to be victims of domestic violence

Zofran bests Diclegis for pregnancy-associated nausea

ADHD stimulant treatment associated with changes in BMI trajectory

Weight loss before gastric bypass may reduce post-operative complications

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Former professional football players may be at greater risk of chronic disease
  • Low-dose pirfenidone may be noninferior to standard dosing in patients with idiopathic pulmonary fibrosis
  • Protein-truncating variants in apolipoprotein B and PCSK9 genes associated with lower exposure to atherogenic LDL cholesterol and risk of coronary heart disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options